Tigecycline T022-10MG

产品介绍

Tigecycline is a broad spectrum glycylcycline antibiotic useful for multi-drug resistant organisms and approved by the FDA in June 2005. Tigecycline is a semisynthetic derivative of tetracycline, that is structurally similar to minocycline; however, it contains a large glycylamido group at the D-9 position. This substitution is thought to be the reason behind its broad-spectrum activity.

Tigecycline is a protein synthesis inhibitor, that show bacteriostatic activity against both Gram-positive and Gram-negative bacteria.  It was designed be less affected by the two major tetracycline-resistance mechanisms, ribosomal protection and efflux. Additionally, Tigecycline is not affected by resistance mechanisms such as beta-lactamases (including extended spectrum beta-lactamases), target-site modifications, macrolide efflux pumps or enzyme target changes (e.g. gyrase/topoisomerases). However, some ESBL-producing isolates may confer resistance to Tigecycline via other resistance mechanisms. Tigecycline resistance in some bacteria (e.g. Acinetobacter calcoaceticus-Acinetobacter baumannii complex) is associated with multi-drug resistant (MDR) efflux pumps.

Tigecycline has recently shown anti-tumor properties and is being evaluated for Tigecycline’s inhibitory effects on several activating signaling pathways and abnormal mitochondrial function in cancer cells.

Tigecycline is soluble in water (0.45 mg/mL) and DMSO (>3 mg/mL).

This product is considered a dangerous good. Quantities above 1 g may be subject to additional shipping fees. Please contact us for specific questions.